Navigation Links
Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases
Date:11/2/2009

te kidney injury (AKI) following major cardiovascular surgery and the prophylaxis of delayed graft function after kidney transplantation. For the structure of these products Quark has licenses from Silence Therapeutics and from Alnylam Pharmaceuticals.

Furthermore, QPI-1007, a proprietary siRNA drug candidate that utilizes a proprietary structure developed by Quark, is being evaluated in advanced IND-enabling preclinical studies as a neuroprotective agent for eye diseases. In addition, Quark has a broad pipeline of siRNA drug candidates and potential drug candidates that have arisen from Quark's research activities. The Company is committed to development of novel siRNA structures and expects to utilize these structures to develop additional RNAi drug candidates.

Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness-Ziona, Israel. Additional information is available at www.quarkpharma.com.

    Quark Pharmaceuticals, Inc.         The Ruth Group (investors / media)
    Juliana Friedman                    Sara Ephraim / Janine McCargo
    +972 89 30 5111                     (646) 536-7004 / 7033
    jfriedman@quarkpharma.com           sephraim@theruthgroup.com
                                        jmccargo@theruthgroup.com

SOURCE Quark Pharmaceuticals, Inc.


'/>"/>
SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
2. Quark Pharmaceuticals Presents at Asia TIDES Conference
3. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
4. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
5. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
6. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
9. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
10. Quark Pharmaceuticals Appoints New Chief Medical Officer
11. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 Egalet ... integrated specialty pharmaceutical company focused on developing, manufacturing ... closing of its previously announced underwritten public offering ... a public offering price of $11.25 per share. ... included 1,000,000 shares issued upon the exercise in ...
(Date:7/31/2015)... 31, 2015 According to a ... Product (Bioimpedance Analyzers (BIA), Dual-Energy X-ray Absorptiometry (DEXA), Skinfold ... Global Analysis & Forecast to 2019", published by MarketsandMarkets, ... $911.1 Million 2014 and is estimated to grow to ... 9.4% from 2014 to 2019. Browse ...
(Date:7/30/2015)... DIEGO , July 30, 2015 /PRNewswire/ ... it has signed a definitive agreement to ... of non-invasive ventilation and sleep-disordered breathing medical ... clinical, innovation and market reputation in China, combined with ResMed,s global leadership in ... people in China ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
... 2011 Reportlinker.com announces that a ... in its catalogue: ... Market 2011-2021 - what are the ... http://www.reportlinker.com/p0578544/Lyophilisation-for-Pharmaceuticals-Technology-and-Services-Market-2011-2021---what-are-the-revenue-prospects.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic What are ...
... Inc. (NASDAQ: CALP ) today reported its financial ... quarter revenue increased to $38.3 million, or 32%, from $29.1 ... excludes the effects of acquisitions, divestitures and currency changes, grew ... a year-to-date basis).  Caliper reported a second quarter net loss ...
Cached Medicine Technology:Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 2Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 3Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 4Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 5Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 6Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 7Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 8Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 9Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 10Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 11Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 12Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects? 13Caliper Life Sciences Reports Second Quarter 2011 Results 2Caliper Life Sciences Reports Second Quarter 2011 Results 3Caliper Life Sciences Reports Second Quarter 2011 Results 4Caliper Life Sciences Reports Second Quarter 2011 Results 5Caliper Life Sciences Reports Second Quarter 2011 Results 6Caliper Life Sciences Reports Second Quarter 2011 Results 7Caliper Life Sciences Reports Second Quarter 2011 Results 8Caliper Life Sciences Reports Second Quarter 2011 Results 9Caliper Life Sciences Reports Second Quarter 2011 Results 10
(Date:7/31/2015)... ... July 31, 2015 , ... Indosoft, Inc., is pleased to announce a ... Q-Suite is their flagship contact center ACD system for Asterisk-based call centers . ... shows the script components to the agent only when wanted, and allows for validation ...
(Date:7/31/2015)... Mirada, CA (PRWEB) , ... July 31, 2015 ... ... Southern California, has announced plans to release a newly redesigned website at Healthpointe.net. ... navigation and enhanced user experience. , The redesign serves to provide smoother ...
(Date:7/31/2015)... , ... July 31, 2015 , ... According to ... a direct result of heroin use and eventual overdoses. Thricefold deaths have held steady ... get a handle on the Sarasota heroin epidemic, which was spurred by the crackdown ...
(Date:7/31/2015)... Metamora, Michigan (PRWEB) , ... July 31, 2015 ... ... 100th baby at Beaumont Hospital's Karmanos Center for Natural Birth . ... mothers looking for a safe natural childbirth experience. With nurses and caregivers that ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... Pediatric Emergency Medicine Practice, and Hospital Medicine Practice, is pleased to announce that ... in a mobile application format available on iPhones, iPads, and Android smartphones and ...
Breaking Medicine News(10 mins):Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2Health News:Healthpointe Announces Newly Redesigned Website 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 3Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 2Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 3
... remove key cue to safety; group seeks legislative help ... be nearly silent, hybrid cars pose a serious threat of ... the American Council of the Blind, which is pushing the ... this danger. , "Traditionally, people who are blind or visually ...
... in Obesity and Weight Management ... ... Inc., the,pioneer in applying advanced technology to emulate a health coaching,session ... management,behavioral health, and medication adherence, is launching HealthMedia(R),Overcoming(TM) Binge Eating. This ...
... PITTSBURGH, July 21 Mylan Inc. (NYSE: ... Crookshank as vice president -,Investor Relations and as ... to Chief Financial Officer Edward J. Borkowski, Crookshank ... as for the,development and direction of activities that ...
... HUNTSVILLE, Ala., July 21 Health,Care Systems, Inc. ... the market leader in medication reconciliation solutions, has ... of the largest,locally owned not-for-profit hospitals in the ... serves as a teaching facility for The,University of ...
... for action from ICANN, US-based domain ... ... an,online pharmacy verification service, and KnujOn.com, an Internet spam and,criminality watchdog, ... illicit sale of anabolic steroids., Steroid abuse is part of ...
... future alternative to bypass surgery, researchers say , , FRIDAY, ... grown in mice the kind of functioning heart blood ... One ultimate goal is to replace some heart surgery ... in the body, providing a system of blood vessels ...
Cached Medicine News:Health News:Hybrid Cars Pose Risk to Blind, Visually Impaired 2Health News:HealthMedia Launches First-Ever Binge Eating Campaign and Intervention to Take on Nation's Top Eating Disorder 2Health News:HealthMedia Launches First-Ever Binge Eating Campaign and Intervention to Take on Nation's Top Eating Disorder 3Health News:HealthMedia Launches First-Ever Binge Eating Campaign and Intervention to Take on Nation's Top Eating Disorder 4Health News:Daniel E. Crookshank Joins Mylan as Vice President - Investor Relations 2Health News:Huntsville Hospital Signs With Health Care Systems, Inc. for Automated Medication Reconciliation Services 2Health News:Kids at Risk: Report Identifies 150 Websites Selling Anabolic Steroids 2Health News:Heart Blood Vessels Grown in the Lab 2
The Vivid e delivers everything you need in a compact echo system, like complete cardiovascular functionality, a comprehensive cardiac measurement and analysis package, and full shared service capabi...
BonePlast is a fast resorbing, osteoconductive bone void filler. By delivering a high dose of calcium to the operative site, BonePlast helps build new bone during the healing process. Packaged in a c...
... The patented telescoping plate ... an anterior plate and vertebral ... design eliminates the need for ... generous amount of bone graft ...
"Small" redefined for Holter recorders!...
Medicine Products: